Table IV.
Adverse events associated with pomalidomide (n=14).
| Grade 3/4 | All grades | |||
|---|---|---|---|---|
| Adverse events | No. | (%) | No. | (%) |
| Hematological | ||||
| Neutropenia | 9 | (64.3) | 9 | (64.3) |
| Anemia | 9 | (64.3) | 11 | (78.6) |
| Thrombocytopenia | 8 | (57.1) | 9 | (64.3) |
| Leukopenia | 8 | (57.1) | 9 | (64.3) |
| Febrile neutropenia | 1 | (7.1) | 1 | (7.1) |
| Non-hematological | ||||
| Infection | 6 | (42.9) | 6 | (42.9) |
| Pneumonia | 2 | (14.3) | 2 | (14.3) |
| Pyrexia | 0 | (0.0) | 6 | (42.9) |
| Fatigue | 4 | (28.6) | 7 | (50.0) |
| Peripheral neuropathy | 0 | (0.0) | 2 | (14.3) |
| Skin rash | 0 | (0.0) | 5 | (35.7) |
| Pruritus | 0 | (0.0) | 4 | (28.6) |
| Edema face | 0 | (0.0) | 1 | (7.1) |
| Increased serum ALT | 1 | (7.1) | 4 | (28.6) |
| Increased serum AST | 0 | (0.0) | 5 | (35.7) |
| Anorexia | 0 | (0.0) | 3 | (21.4) |
| Constipation | 1 | (7.1) | 4 | (28.6) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.